Marksans Pharma Q4 Results FY24-25, Revenue ₹709 Cr, PAT ₹91 Cr, FY PAT Up 21.5%

Synopsis:

Marksans Pharma reported ₹709 crore in consolidated revenue and ₹91 crore in net profit for Q4 FY25. For the full year, revenue stood at ₹2,623 crore, with net profit growing 21.5% YoY, driven by robust performance across global markets..

Key Highlights / Quick Insights

  • Q4 FY25 Revenue: ₹708.5 crore, up 26.5% YoY

  • Q4 FY25 PAT: ₹90.7 crore, up 16.9% YoY

  • FY25 Revenue: ₹2,622.8 crore, up 20.5% YoY

  • FY25 PAT: ₹382.6 crore, up 21.5% YoY

  • EBITDA for FY25 stood at ₹528.6 crore; EBITDA margin was 20.2%

  • EPS for FY25 rose to ₹8.4 from ₹6.9 in FY24

  • Gross Margin improved by 407 bps YoY to 56.4%

Marksans Pharma Limited

Trade

263.02-2.96 (-1.11 %)

Updated - 24 June 2026
275.50day high
DAY HIGH
261.10day low
DAY LOW
3426966
VOLUME (BSE)

Quarterly – Marksans Pharma Q4 Results FY24-25

Particulars

Q4 FY25

Q4 FY24

YoY Change

Operating Revenue (₹ crore)

708.5

560.0

+26.5%

Gross Profit (₹ crore)

383.2

290.2

+32.1%

Gross Margin (%)

54.1%

51.8%

+228 bps

EBITDA (₹ crore)

125.8

109.6

+14.7%

EBITDA Margin (%)

17.8%

19.6%

-183 bps

PAT (₹ crore)

90.7

77.6

+16.9%

Net Margin (%)

12.5%

13.5%

-95 bps

EPS (₹)

2.0

1.7

+15.7%

Segment Highlights

Segment

Q4 FY25 (₹ Cr)

Q4 FY24 (₹ Cr)

YoY Growth

FY25 (₹ Cr)

FY24 (₹ Cr)

YoY Growth

Share of FY25 Revenue

US & North America

328.6

245.0

+34.1%

1,236.6

918.1

+34.7%

47.1%

UK & Europe

274.1

232.8

+17.7%

1,029.8

943.0

+9.2%

39.3%

Australia & New Zealand

76.5

63.3

+20.9%

252.8

218.8

+15.5%

9.6%

Rest of World (RoW)

29.3

18.9

+55.0%

103.7

97.4

+6.4%

4.0%

Total Revenue

708.5

560.0

+26.5%

2,622.8

2,177.4

+20.5%

100%

Sector Expectations for Marksans Pharma Q4 Results FY24-25

Marksans Pharma’s 21.5% rise in FY25 net profit and 20.5% revenue growth align with the broader industry’s focus on US market penetration and operational scalability. Performance across OTC and formulation segments was in line with evolving global demand trends.

Management Commentary

“We are pleased to announce another year of robust performance; we have achieved highest ever annual revenues and profits. In FY25, we witnessed strong performance across all our markets, the US market has been a key growth driver with 35% YoY increase in revenue. Our OTC segment’s performance is at all-time high, crossing INR 2000 Crs in revenue, a testament to our focus and execution on expanding the OTC product pipeline. Looking forward, we continue to strengthen our foundation by increasing the capacity and strengthening our product pipeline. We are optimistic about building on this momentum and create more value for our stakeholders in the coming years.”

Share this article: 

Published Date : 19 May 2025

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.


Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

QR code to download Bajaj Broking App

9 lakh+ Users

icon-with-text

4.9 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,300 Cr+ MTF Book

icon-with-text